Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Conditions
Hemorrhage, Gastrointestinal, Myocardial Infarction, Stroke, Kidney Diseases
Interventions
Not listed
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
144,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Raritan, New Jersey
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Conditions
Cardio-Renal Syndrome, Heart Failure, Chronic Kidney Diseases
Interventions
Fibroblast Growth Factor 23
Diagnostic Test
Lead sponsor
Coney Island Hospital, Brooklyn, NY
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Congenital Heart Disease, Cardiopulmonary Bypass, Myocardial Injury, Acute Kidney Injury, Acute Lung Injury
Interventions
RIPC, Control
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Kidney Injury, Hypoxic-Ischemic Encephalopathy, Caffeine
Interventions
Caffeine citrate
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 24 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Little Rock, Arkansas
Completed Phase 4 Interventional Results available

ISCHEMIA-Chronic Kidney Disease Trial

NCT01985360
Conditions
Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia, Kidney Disease, End Stage Renal Failure on Dialysis
Interventions
Cardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention, Lifestyle, Medication
Procedure · Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Death, Postoperative Complications, Myocardial Infarction, Stroke, Renal Failure
Interventions
FACE quality improvement initiative (see below), Pre-quality improvement initiative
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • St Louis, Missouri
Conditions
Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
Interventions
Bendavia, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting No phase listed Observational Accepts healthy volunteers

BRINK (BRain In Kidney Disease) Memory Study 2.0

NCT04975464
Conditions
Chronic Kidney Diseases, Dementia, Dementia, Vascular, Stroke, Alzheimer Disease, Cognitive Decline, Cognitive Impairment, Cognitive Dysfunction, Kidney Diseases, Diabetes, Cerebral Atrophy, Small Vessel Ischemic Disease
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota
Conditions
Acute Kidney Injury
Interventions
Ischemic preconditionin
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
Interventions
CoQ10 1200 mg orally with Glutathione 1000 mg orally, Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Kidney Neoplasms
Interventions
Cryoablation Assisted Partial Nephrectomy
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
55 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2041
U.S. locations
1
States / cities
Miami Lakes, Florida
Conditions
Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
Interventions
Remote ischemic preconditioning, Sham remote ischemic conditioning
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Dallas, Texas • Richmond, Virginia
Conditions
Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions
paricalcitol, placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
Interventions
Best Practice, Tocilizumab
Other · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Atlanta, Georgia
Completed No phase listed Observational Accepts healthy volunteers

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

NCT00563901
Conditions
Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Contrast-induced Acute Kidney Injury
Interventions
RIPC, Sham-RIPC
Device
Lead sponsor
Oladipupo Olafiranye, MD, MS
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Interventions
Clopidogrel, Clopidogrel active metabolite
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida